期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 15, 期 9, 页码 1116-1121出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2009.05.019
关键词
Infliximab; Steroid-refractory; Acute graft-versus-host disease
资金
- National Cancer Center [3 P30-CA7692, 5 K12-CA087989]
- National Center for Research Resources [K30-RR022270]
Infliximab has demonstrated activity in the treatment of steroid-refractory acute graft-versus-host disease (aGVHD). We aimed to confirm the effectiveness of infliximab as a salvage therapy for steroid-refractory aGVHD. In a series of 52 patients, 71% of whom had grade III-IV aGVHD, only 15% achieved complete remission (CR) with the use of infliximab alone as salvage therapy. CR of aGVHD differed according to overall aGVHD grade at salvage (grade II, 5/15; grade III, 2/17; grade IV, 1/20; P = .03). Median overall survival (OS) was only 1.7 months (95% confidence interval [CI] = 0.99 to 2.3 months). CR of aGVHD was significantly associated with OS, with a hazard ratio of 8.4 for death in those without CR (95% CI = 3.6 to 19.6; P < .0001). This series demonstrates the limited activity of infliximab in patients with high-grade aGVHD. Further work is needed to identify effective therapy for aGVHD. Biol Blood Marrow; Transplant 15: 1116-1121 (2009) (C) 2009 American Society for Blood and Marrow Transplantation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据